Gilead shifts cystic fibrosis drug to CURx Pharma in licensing deal
February 20, 2014 at 15:28 PM EST
Gilead Sciences Inc. licensed to CURx Pharmaceuticals a late-stage treatment for lung infection in cystic fibrosis patients...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|